SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
杜彦君
Lv1
10 积分
2024-01-08 加入
最近求助
最近应助
互助留言
Discovery of a novel potent EGFR inhibitor against EGFR activating mutations and on-target resistance in NSCLC
1个月前
已完结
OA03.04 A Phase 1b Study Of Furmonertinib, an Oral, Brain Penetrant, Selective EGFR Inhibitor, in Patients with Advanced NSCLC with EGFR Exon 20 Insertions
1个月前
已完结
1123P Real-world outcomes of first-line osimertinib for EGFR mutated advanced NSCLC patients in China: Interim analysis of the FLOURISH study
1个月前
已完结
PL03.13 Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2)
1个月前
已完结
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
1个月前
已完结
[Expert consensus on the treatment of chronic kidney disease with tuberculosis (2022 version)]
1个月前
已完结
Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations
2个月前
已完结
[Expert consensus on diagnosis and treatment of malignant pleural effusion caused by lung cancer]
3个月前
已完结
Micropapillary and Solid Histologic Patterns in N1 and N2 Lymph Node Metastases Are Independent Factors of Poor Prognosis in Patients With Stages II to III Lung Adenocarcinoma
3个月前
已完结
Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations
3个月前
已完结
没有进行任何应助
没有进行任何互助留言
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论